RENEE HARRIS: Open Payments
NPI 1043350895 · BLOOMFIELD HILLS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,097 in 47 payments from 14 companies in 2025. Trend: 2023 $650 · 2024 $491 · 2025 $1,097
Food & beverage: $1,097
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $370 |
| Otsuka America Pharmaceutical, Inc. | 14 | $214 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $160 |
| Janssen Pharmaceuticals, Inc | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $37 |
| Noven Therapeutics, LLC | 2 | $33 |
| Alkermes, Inc. | 1 | $31 |
| Gilead Sciences, Inc. | 1 | $30 |
Products named: COBENFY, REXULTI, CAPLYTA, INVEGA SUSTENNA, INGREZZA, HETLIOZ, Xelstrym, ARISTADA.
Industry payments across MI — which companies pay providers there.
